

Herstellung und Anwendung antiviraler T-Zellen von verwandten und unverwandten Third-Party-Spendern zur Behandlung viraler Komplikationen in immungeschwächten Patienten und Prävention schwerer Verläufe bei künftigen Pandemien

1. Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrych M. Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions. *Front Pediatr* 2021 9:786017. <https://doi.org/10.3389/fped.2021.786017>.
2. Clausen ES, Zaffiri L. Infection prophylaxis and management of viral infection. *Ann Transl Med* 2020 Mar;8(6):415. <https://doi.org/10.21037/atm.2019.11.85>.
3. Mehta RS, Rezvani K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. *Virulence* 2016 Nov 16;7(8):901-916. <https://doi.org/10.1080/21505594.2016.1208866>.
4. Roberts MB, Fishman JA. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the "Net State of Immunosuppression". *Clin Infect Dis* 2021 Oct 5;73(7):e1302-e1317. <https://doi.org/10.1093/cid/ciaa1189>.
5. Annaloro C, Serpenti F, Saporiti G, Galassi G, Cavallaro F, Grifoni F, Goldaniga M, Baldini L, Onida F. Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications. *Front Immunol* 2020 11:569381. <https://doi.org/10.3389/fimmu.2020.569381>.
6. Ouellette CP. Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection. *Viruses* 2022 Oct 27;14(11). <https://doi.org/10.3390/v14112370>.
7. Saullo JL, Miller RA. Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients. *Annu Rev Med* 2023 Jan 27;74:89-105. <https://doi.org/10.1146/annurev-med-042921-124739>.
8. Zavras P, Su Y, Fang J, Stern A, Gupta N, Tang Y, Raval A, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. *Biol Blood Marrow Transplant* 2020 Aug;26(8):1482-1491. <https://doi.org/10.1016/j.bbmt.2020.03.019>.
9. Fatima A, Haddad SF, Johnny Z, Kanj SS. Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants. *Int J Antimicrob Agents* 2023 May 21;62(2):106860. <https://doi.org/10.1016/j.ijantimicag.2023.106860>.
10. El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R, Chemaly RF. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. *J Med Virol* 2020 Jan;92(1):86-95. <https://doi.org/10.1002/jmv.25574>.
11. Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies. *Open Forum Infect Dis* 2023 Jan;10(1):ofac687. <https://doi.org/10.1093/ofid/ofac687>.
12. Liu LW, Yn A, Gao F, Olson M, Crain M, Abboud R, Westervelt P, Abboud C, Vij R, Stockerl-Goldstein K, Pusic I, Cashen AF, Schroeder MA. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. *Transplant Cell Ther* 2022 Aug;28(8):510 e511-510 e519. <https://doi.org/10.1016/j.jtct.2022.05.020>.
13. Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M, Investigators ST. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. *Clin Infect Dis* 2022 Sep 10;75(4):690-701. <https://doi.org/10.1093/cid/ciab988>.
14. Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. *Clin Infect Dis* 2019 Apr 8;68(8):1255-1264. <https://doi.org/10.1093/cid/ciy706>.
15. Möhn N, Grote-Levi L, Hopfner F, Eiz-Vesper B, Maecker-Kolhoff B, Warnke C, Suhs KW, Wattjes MP, Hoglinger GU, Skripuletz T. Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. *J Neurol* 2022 May;269(5):2403-2413. <https://doi.org/10.1007/s00415-021-10952-5>.
16. Jakharia N, Subramanian AK, Shapiro AE. COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. *Infect Dis Clin North Am* 2022 Jun;36(2):397-421. <https://doi.org/10.1016/j.idc.2022.01.006>.
17. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023 Mar;21(3):133-146. <https://doi.org/10.1038/s41579-022-00846-2>.
18. Bonifacius A, Tischer-Zimmermann S, Dragon AC, Gussarow D, Vogel A, Krettek U, Godecke N, Yilmaz M, Kraft ARM, Hoepfer MM, Pink I, Schmidt JJ, Li Y, Welte T, Maecker-Kolhoff B, Martens J, Berger MM, Lobenwein C, Stankov MV, Cornberg M, David S, Behrens GMN, Witzke O, Blasczyk R, Eiz-Vesper B. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. *Immunity* 2021 Feb 9;54(2):340-354 e346. <https://doi.org/10.1016/j.immuni.2021.01.008>.

19. Mishra KP, Singh M, Saraswat D, Ganju L, Varshney R. Dysfunctional State of T Cells or Exhaustion During Chronic Viral Infections and COVID-19: A Review. *Viral Immunol* 2022 May;35(4):284-290. <https://doi.org/10.1089/vim.2022.0002>.
20. Toori KU, Qureshi MA, Chaudhry A. Lymphopenia: A useful predictor of COVID-19 disease severity and mortality. *Pak J Med Sci* 2021 Nov-Dec;37(7):1984-1988. <https://doi.org/10.12669/pjms.37.7.4085>.
21. Vazquez-Alejo E, Tarancon-Diez L, Espinar-Buitrago MS, Genebat M, Calderon A, Perez-Cabeza G, Magro-Lopez E, Leal M, Munoz-Fernandez MA. Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study. *J Clin Med* 2023 May 18;12(10). <https://doi.org/10.3390/jcm12103539>.
22. Acquier M, Taton B, Alain S, Garrigue I, Mary J, Pfirmann P, Visentin J, Hantz S, Merville P, Kaminski H, Couzi L. Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance. *Open Forum Infect Dis* 2023 Feb;10(2):ofad018. <https://doi.org/10.1093/ofid/ofad018>.
23. Stanojevic M, Bertaina A, Bonfim C, Ciccocioppo R, Cohen S, Purtill D, Ruggeri A, Russell A, Sharma A, Wynn R, Boelens JJ, Prockop S, Abraham A, engineering Iwosc. Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. *Cytotherapy* 2022 Sep;24(9):884-891. <https://doi.org/10.1016/j.jcyt.2022.05.010>.
24. Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. *J Hematol Oncol* 2019 Feb 6;12(1):13. <https://doi.org/10.1186/s13045-019-0701-1>.
25. Motta CM, Keller MD, Bollard CM. Applications of virus-specific T cell therapies post-BMT. *Semin Hematol* 2023 Jan;60(1):10-19. <https://doi.org/10.1053/j.seminhematol.2022.12.002>.
26. Ottaviano G, Chiesa R, Feuchtinger T, Vickers MA, Dickinson A, Gennery AR, Veys P, Todryk S. Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation. *Cells* 2019 Jan 14;8(1). <https://doi.org/10.3390/cells8010047>.
27. Dholaria B, Savani BN, Labopin M, Luznik L, Ruggeri A, Mielke S, Al Malki MM, Kongtim P, Fuchs E, Huang XJ, Locatelli F, Aversa F, Castagna L, Bacigalupo A, Martelli M, Blaise D, Ben Soussan P, Arnault Y, Handgretinger R, Roy DC, O'Donnell P, Bashey A, Solomon S, Romee R, Lewalle P, Gayoso J, Maschan M, Lazarus HM, Ballen K, Giebel S, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. *Haematologica* 2020 Jan;105(1):47-58. <https://doi.org/10.3324/haematol.2019.219790>.
28. Bonifacius A, Tischer-Zimmermann S, Santamorenna MM, Mausberg P, Schenk J, Koch S, Barnstorf-Brandes J, Godecke N, Martens J, Goudeva L, Verboom M, Wittig J, Maecker-Kolhoff B, Baurmann H, Clark C, Brauns O, Simon M, Lang P, Cornely OA, Hallek M, Blasczyk R, Seiferling D, Kohler P, Eiz-Vesper B. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. *Front Bioeng Biotechnol* 2022 10:867042. <https://doi.org/10.3389/fbioe.2022.867042>.
29. Bunos M, Hummer C, Wingenfeld E, Sorg N, Pfirmann V, Bader P, Seifried E, Bonig H. Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. *Vox Sang* 2015 Nov;109(4):387-393. <https://doi.org/10.1111/vox.12291>.
30. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE, Perna SK, Ennamuri S, Gottschalk S, Brenner MK, Heslop HE, Rooney CM, Leen AM. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. *Mol Ther* 2012 Aug;20(8):1622-1632. <https://doi.org/10.1038/mt.2012.130>.
31. Gooptu M, Antin JH. GVHD Prophylaxis 2020. *Front Immunol* 2021 12:605726. <https://doi.org/10.3389/fimmu.2021.605726>.
32. Mangare C, Tischer-Zimmermann S, Bonifacius A, Riese SB, Dragon AC, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Variances in Antiviral Memory T-Cell Repertoire of CD45RA- and CD62L-Depleted Lymphocyte Products Reflect the Need of Individual T-Cell Selection Strategies to Reduce the Risk of GvHD while Preserving Antiviral Immunity in Adoptive T-Cell Therapy. *Transfus Med Hemother* 2022 Feb;49(1):30-43. <https://doi.org/10.1159/000516284>.
33. Naik S, Triplett BM. Selective depletion of naive T cells by targeting CD45RA. *Front Oncol* 2022 12:1009143. <https://doi.org/10.3389/fonc.2022.1009143>.
34. Vasileiou S, Turney AM, Kuvalekar M, Mukhi SS, Watanabe A, Lulla P, Ramos CA, Naik S, Vera JF, Tzannou I, Leen AM. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. *Haematologica* 2020 Jan;105(1):235-243. <https://doi.org/10.3324/haematol.2018.206896>.
35. Barrett AJ, Prockop S, Bollard CM. Reprint of: Virus-Specific T Cells: Broadening Applicability. *Biol Blood Marrow Transplant* 2018 Mar;24(3S):S1-S6. <https://doi.org/10.1016/j.bbmt.2017.12.787>.
36. Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft HG, Arseniev L, Beier R, Beutel G, Cario G, Frohlich B, Greil J, Hansmann L, Hasenkamp J, Hofs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kroger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt HC, Sala E, Sauer MG, Schmitt C, Schroers R, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. *J Clin Invest* 2023 Jun 15;133(12). <https://doi.org/10.1172/JCI163548>.
37. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. *Blood* 2007 Aug 15;110(4):1123-1131. <https://doi.org/10.1182/blood-2006-12-063008>.

38. O'Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections. *Bone Marrow Transplant* 2016 Sep;51(9):1163-1172. <https://doi.org/10.1038/bmt.2016.17>.
39. Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M, Lakshmiipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kroger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. *Leukemia* 2017 Oct;31(10):2161-2171. <https://doi.org/10.1038/leu.2017.16>.
40. Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. *Transplant Cell Ther* 2023 May;29(5):305-310. <https://doi.org/10.1016/j.jtct.2023.01.027>.
41. Grote-Levi L, Mohn N, Bonifacius A, Tischer-Zimmermann S, Schweitzer F, Mahmoudi N, Silling S, Maecker-Kolhoff B, Eiz-Vesper B, Hoglinger GU, Skripuletz T. Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report. *J Neurol* 2023 May.
42. Hansen BT, Bacher P, Eiz-Vesper B, Heckl SM, Klapper W, Koch K, Maecker-Kolhoff B, Baldus CD, Fransecky L. Adoptive Cell Transfer of Allogeneic Epstein-Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report. *Front Immunol* 2021 12:727814. <https://doi.org/10.3389/fimmu.2021.727814>.
43. Hopfner F, Mohn N, Eiz-Vesper B, Maecker-Kolhoff B, Gottlieb J, Blasczyk R, Mahmoudi N, Pars K, Adams O, Stangel M, Wattjes MP, Hoglinger G, Skripuletz T. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. *Neurol Neuroimmunol Neuroinflamm* 2021 Jul;8(4). <https://doi.org/10.1212/NXI.000000000001020>.
44. Jiang W, Clancy LE, Avdic S, Suttrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, Myers N, Micklethwaite KP, Antonenas V, Selim AG, Ritchie D, Bateman CM, Shaw PJ, Blyth E, Gottlieb DJ. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. *Blood Adv* 2022 Sep 13;6(17):4949-4966. <https://doi.org/10.1182/bloodadvances.2022007103>.
45. Koldehoff M, Eiz-Vesper B, Maecker-Kolhoff B, Steckel NK, Dittmer U, Horn PA, Lindemann M. Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients. *Vaccines (Basel)* 2023 Apr 14;11(4). <https://doi.org/10.3390/vaccines11040845>.
46. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood* 2013 Jun 27;121(26):5113-5123. <https://doi.org/10.1182/blood-2013-02-486324>.
47. Papadopoulou A, Alvanou M, Karavalakis G, Tzannou I, Yannaki E. Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond. *Hemasphere* 2023 Jan;7(1):e809. <https://doi.org/10.1097/HS9.0000000000000809>.
48. Prockop SE, Hasan A, Doubrovina E, Dahi PB, Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao J, Arcila M, Boulad F, Castro-Malaspina H, Cho C, Curran KJ, Giralt S, Kernan NA, Koehne G, Jakubowski A, Papadopoulou E, Perales MA, Politikos I, Price K, Selvakumar A, Sauter CS, Tamari R, Vizconde T, Young JW, O'Reilly RJ. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant. *J Clin Invest* 2023 May 15;133(10). <https://doi.org/10.1172/JCI165476>.
49. Schultze-Florey RE, Tischer S, Kuhlmann L, Hundsdoerfer P, Koch A, Anagnostopoulos I, Ravens S, Goudeva L, Schultze-Florey C, Koenecke C, Blasczyk R, Koehl U, Heuft HG, Prinz I, Eiz-Vesper B, Maecker-Kolhoff B. Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease. *Front Immunol* 2018 9:1475. <https://doi.org/10.3389/fimmu.2018.01475>.
50. Wicklein R, Heidegger S, Verbeek M, Eiz-Vesper B, Maecker-Kolhoff B, Kirschke JS, Page A, Korn T, Hemmer B, Deschauer M. Combined Treatment With Pembrolizumab and Allogeneic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report. *Neurol Neuroimmunol Neuroinflamm* 2021 Jul;8(5). <https://doi.org/10.1212/NXI.000000000001042>.
51. Geyeregger R, Freimuller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, Lion T, Rammensee HG, Fischer G, Eiz-Vesper B, Lawitschka A, Matthes S, Fritsch G. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. *PLoS One* 2013 8(4):e59592. <https://doi.org/10.1371/journal.pone.0059592>.
52. Harris KM, Davila BJ, Bollard CM, Keller MD. Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. *J Allergy Clin Immunol Pract* 2019 Mar;7(3):809-818. <https://doi.org/10.1016/j.jaip.2018.10.049>.
53. Withers B, Clancy L, Burgess J, Simms R, Brown R, Micklethwaite K, Blyth E, Gottlieb D. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program. *Biol Blood Marrow Transplant* 2018 Dec;24(12):2433-2442. <https://doi.org/10.1016/j.bbmt.2018.08.024>.
54. Heslop HE, Sharma S, Rooney CM. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. *J Clin Oncol* 2021 Feb 10;39(5):514-524. <https://doi.org/10.1200/JCO.20.01709>.
55. Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. *Sci Transl Med* 2014 Jun 25;6(242):242ra283. <https://doi.org/10.1126/scitranslmed.3008825>.

56. Gerdemann U, Katari UL, Papadopoulou A, Keirnan JM, Craddock JA, Liu H, Martinez CA, Kennedy-Nasser A, Leung KS, Gottschalk SM, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. *Mol Ther* 2013 Nov;21(11):2113-2121. <https://doi.org/10.1038/mt.2013.151>.
57. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. *Nat Med* 2006 Oct;12(10):1160-1166. <https://doi.org/10.1038/nm1475>.
58. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ, Crawford DH. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. *Lancet* 2002 Aug 10;360(9331):436-442. [https://doi.org/10.1016/S0140-6736\(02\)09672-1](https://doi.org/10.1016/S0140-6736(02)09672-1).
59. Vickers MA, Wilkie GM, Robinson N, Rivera N, Haque T, Crawford DH, Barry J, Fraser N, Turner DM, Robertson V, Dyer P, Flanagan P, Newlands HR, Campbell J, Turner ML. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. *Br J Haematol* 2014 Nov;167(3):402-410. <https://doi.org/10.1111/bjh.13051>.
60. Rubinstein J, Toner K, Gross T, Wistinghausen B. Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. *Best Pract Res Clin Haematol* 2023 Mar;36(1):101446. <https://doi.org/10.1016/j.beha.2023.101446>.
61. Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. *J Clin Oncol* 2017 Nov 1;35(31):3547-3557. <https://doi.org/10.1200/JCO.2017.73.0655>.
62. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. *Blood* 2012 Mar 15;119(11):2644-2656. <https://doi.org/10.1182/blood-2011-08-371971>.
63. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. *Blood* 2010 Feb 4;115(5):925-935. <https://doi.org/10.1182/blood-2009-08-239186>.
64. Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. *Br J Haematol* 2019 Oct;187(2):206-218. <https://doi.org/10.1111/bjh.16053>.
65. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. *Lancet* 1995 Jan 7;345(8941):9-13. [https://doi.org/10.1016/s0140-6736\(95\)91150-2](https://doi.org/10.1016/s0140-6736(95)91150-2).
66. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. *N Engl J Med* 2018 Oct 11;379(15):1443-1451. <https://doi.org/10.1056/NEJMoa1801540>.
67. Cortese I, Beck ES, Al-Louzi O, Ohayon J, Andrada F, Osuorah I, Dwyer J, Billioux BJ, Dargah-Zada N, Schindler MK, Binder K, Reoma L, Norato G, Enose-Akahata Y, Smith BR, Monaco MC, Major EO, Jacobson S, Stroncek D, Highfill S, Panch S, Reich DS, Barrett J, Nath A, Muranski P. BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study. *Lancet Neurol* 2021 Aug;20(8):639-652. [https://doi.org/10.1016/S1474-4422\(21\)00174-5](https://doi.org/10.1016/S1474-4422(21)00174-5).
68. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high risk patients. *Haematologica* 2022 Nov 10. <https://doi.org/10.3324/haematol.2022.281946>.
69. Priesner C, Esser R, Tischer S, Marburger M, Aleksandrova K, Maecker-Kolhoff B, Heuft HG, Goudeva L, Blasczyk R, Arseniev L, Kohl U, Eiz-Vesper B, Kloss S. Comparative Analysis of Clinical-Scale IFN-gamma-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms. *Front Immunol* 2016 7:393. <https://doi.org/10.3389/fimmu.2016.00393>.
70. Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, Kloess S, Arseniev L, Aleksandrova K, Maecker-Kolhoff B, Blasczyk R, Koehl U, Eiz-Vesper B. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. *J Transl Med* 2014 12:336. <https://doi.org/10.1186/s12967-014-0336-5>.
71. Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft HG, Verboom M, Immenschuh S, Heim A, Borchers S, Mischak-Weissinger E, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. *Biol Blood Marrow Transplant* 2013 Oct;19(10):1480-1492. <https://doi.org/10.1016/j.bbmt.2013.07.015>.

72. Barba P, Roldan E, Suárez-Lledó M, Montoro Gomez J, Perez-Hoyos S, Mussetti A, Ferra C, Coll R, Rodriguez L, Marsal J, Martino R, Castaño J, Codinach M, Bosch F, Gimeno R, Valcarcel D, Rudilla F, Querol S. Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry. *Blood* 2022 140. <https://doi.org/10.1182/blood-2022-165943>.
73. Feuchtinger T, Opher K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, Mohty M, Or R, Maschan M, Schumm M, Hamprecht K, Handgretinger R, Lang P, Einsele H. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. *Blood* 2010 Nov 18;116(20):4360-4367. <https://doi.org/10.1182/blood-2010-01-262089>.
74. Kallay K, Kassa C, Reti M, Karaszi E, Sinko J, Goda V, Strehn A, Csordas K, Horvath O, Szederjesi A, Tasnady S, Hardi A, Krivan G. Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation. *J Immunother* 2018 Apr;41(3):158-163. <https://doi.org/10.1097/CJI.000000000000197>.
75. Qasim W, Gilmour K, Zhan H, Derniame S, McNicol AM, Ip W, Hiwarkar P, Veys P, Gaspar HB. Interferon-gamma capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. *Br J Haematol* 2013 May;161(3):449-452. <https://doi.org/10.1111/bjh.12251>.
76. Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralto S, Chari A, Jagannath S, Koehne G. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. *Biol Blood Marrow Transplant* 2016 Feb;22(2):258-267. <https://doi.org/10.1016/j.bbmt.2015.08.025>.
77. Peggs KS, Thomson K, Samuel E, Dyer G, Armoogum J, Chakraverty R, Pang K, Mackinnon S, Lowdell MW. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. *Clin Infect Dis* 2011 Jan 1;52(1):49-57. <https://doi.org/10.1093/cid/ciq042>.
78. Qasim W, Derniame S, Gilmour K, Chiesa R, Weber M, Adams S, Rao K, Amrolia P, Goulden N, Veys P, Gaspar H. Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. *Br J Haematol* 2011 Jul;154(1):150-153. <https://doi.org/10.1111/j.1365-2141.2011.08579.x>.
79. Meedt E, Weber D, Bonifacius A, Eiz-Vesper B, Maecker-Kolhoff B, Delecluse S, Delecluse HJ, Lorenz M, Schwarz K, Meedt ST, Braess J, Herr W, Holler E, Edinger M, Wolff D. Chronic Active Epstein-Barr Virus (EBV) Infection Controlled by Allogeneic Stem Cell Transplantation and EBV-Specific T Cells. *Clin Infect Dis* 2023 Jun 16;76(12):2200-2202. <https://doi.org/10.1093/cid/ciad131>.
80. Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, Persinger H, Hilzinger B, Martin PJ, Carpenter PA, Flowers ME, Voutsinas J, Gooley TA, Loeb K, Wood BL, Heimfeld S, Riddell SR, Shlomchik WD. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. *J Clin Oncol* 2022 Apr 10;40(11):1174-1185. <https://doi.org/10.1200/JCO.21.01755>.
81. Mangare C, Tischer-Zimmermann S, Riese SB, Dragon AC, Prinz I, Blasczyk R, Maecker-Kolhoff B, Eiz-Vesper B. Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads. *Int J Mol Sci* 2019 Mar 20;20(6). <https://doi.org/10.3390/ijms20061415>.
82. Muller N, Landwehr K, Langeveld K, Stenzel J, Pouwels W, van der Hoorn M, Seifried E, Bonig H. Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells. *Cytotherapy* 2018 Apr;20(4):532-542. <https://doi.org/10.1016/j.jcyt.2018.01.006>.
83. Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, Shlomchik W. Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. *Biol Blood Marrow Transplant* 2014 May;20(5):705-716. <https://doi.org/10.1016/j.bbmt.2014.01.032>.
84. Castagna L, Valli V, Timofeeva I, Capizzuto R, Bramanti S, Mariotti J, De Philippis C, Sarina B, Mannina D, Giordano L, De Paoli F, van Beek JJP, Zaghi E, Calvi M, Vito CD, Mavilio D, Crocchiolo R, Lugli E. Feasibility and Efficacy of CD45RA+ Depleted Donor Lymphocytes Infusion After Haploidentical Transplantation With Post-Transplantation Cyclophosphamide in Patients With Hematological Malignancies. *Transplant Cell Ther* 2021 Jun;27(6):478 e471-478 e475. <https://doi.org/10.1016/j.jtct.2021.03.010>.
85. Yuste JR, Lopez-Diaz de Cerio A, Rifon J, Moreno C, Panizo M, Inoges S. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients. *Antivir Ther* 2019 24(4):313-319. <https://doi.org/10.3851/IMP3307>.
86. Ferreras C, Pascual-Miguel B, Mestre-Duran C, Navarro-Zapata A, Clares-Villa L, Martin-Cortazar C, De Paz R, Marcos A, Vicario JL, Balas A, Garcia-Sanchez F, Eguizabal C, Solano C, Mora-Rillo M, Soria B, Perez-Martinez A. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy. *Front Cell Dev Biol* 2021 9:620730. <https://doi.org/10.3389/fcell.2021.620730>.
87. Perez-Martinez A, Mora-Rillo M, Ferreras C, Guerra-Garcia P, Pascual-Miguel B, Mestre-Duran C, Borobia AM, Carcas AJ, Queiruga-Parada J, Garcia I, Sanchez-Zapardiel E, Gasior M, De Paz R, Marcos A, Vicario JL, Balas A, Moreno MA, Eguizabal C, Solano C, Arribas JR, Buckley RM, Montejano R, Soria B. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). *EClinicalMedicine* 2021 Sep;39:101086. <https://doi.org/10.1016/j.eclinm.2021.101086>.